Everyone is looking for the next wave of ASX breakouts because they happen in every market cycle. Investors still look back at those stories as proof that the ASX can…
Investing in ASX biotechs is a risky business, even more than most other companies on the market. Unless you own one of the large cap biotechs, you are betting that…
Here are 5 ASX biotechs expecting clinical trial results in the next few months!
Dimerix (ASX:DXB)
Dimerix is in the middle of a Phase III trial or its DMX-200 drug…